MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma

Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma

(2017) Huiying Xue et al.   International Journal of Nanomedicine

MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expression

(2017) Changmei Hu et al.   Oncology Letters

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways

(2016) Yanmin Xu et al.   CANCER LETTERS

miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression

(2016) Junya Azumi et al.   CANCER SCIENCE

Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF

(2016) Jiwen Cheng et al.   Oncotarget

MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1

(2015) Jing-Jun Yan et al.   Oncotarget

Potential involvement of miR-375 in the premalignant progression of oral squamous cell carcinoma mediated via transcription factor KLF5

(2015) Wen Shi et al.   Oncotarget

MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway

(2015) Changjun He et al.   Oncotarget

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2

(2014) Li Ma et al.   CANCER LETTERS

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells

(2014) Dali Zhao et al.   CELLULAR SIGNALLING

MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway

(2014) JIAN ZHOU et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice

(2014) Fuyuan Li et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

(2014) B. Zhai et al.   MOLECULAR CANCER THERAPEUTICS

c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2α and promotes tumor angiogenesis and metastasis by upregulating FGF2

(2014) G Xue et al.   ONCOGENE

miR-375 Inhibits Proliferation of Mouse Pancreatic Progenitor Cells by Targeting YAP1

(2013) Zhen-Wu Zhang et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Molecular Targeted Therapies in Hepatocellular Carcinoma

(2012) Shinji Tanaka et al.   SEMINARS IN ONCOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo

(2011) X-X He et al.   ONCOGENE

Molecular Mechanism of Chemoresistance by Astrocyte Elevated Gene-1

(2010) B. K. Yoo et al.   CANCER RESEARCH

Tumor angiogenesis and novel antiangiogenic strategies

(2009) Michael S. Gordon et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE